BioStem Technologies, Inc. (BSEM)
| Market Cap | 72.59M -61.3% |
| Revenue (ttm) | 37.65M -88.7% |
| Net Income | -19.31M |
| EPS | -1.15 |
| Shares Out | 17.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,312 |
| Open | 4.100 |
| Previous Close | 4.090 |
| Day's Range | 4.090 - 4.270 |
| 52-Week Range | 3.093 - 14.150 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+69.08%) |
| Earnings Date | Aug 12, 2026 |
About BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human conne... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies announces notice of allowance for four patents
BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, or USPTO, has issued notices of allowance for four new divisional U.S. design patent applications related to i...
BioStem Technologies Transcript: 16th Annual LD Micro Invitational Conference
Q1 revenue reached $6.1M with a 61% margin, and the BioTissue acquisition expanded the addressable market to $23B and diversified the payer mix. Nasdaq uplisting is in progress, with a capital raise planned to boost institutional ownership and support growth initiatives.
BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioStem Technologies (BSEM) to $7 from $9 and keeps a Buy rating on the shares. The firm said that the physician-office channel…
BioStem Technologies Earnings Call Transcript: Q1 2026
Q1 2026 marked a strategic shift to the hospital channel, with $6.1M revenue and strong integration of acquired assets. Guidance for 2026 is $25–29M, driven by sales force expansion and margin improvement from in-house manufacturing targeted for 2027.
BioStem Technologies Earnings release: Q1 2026
BioStem Technologies released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Biostem Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Biostem Technologies (BSEM) with a Buy rating and $9 price target While the decline in industry revenues has resulted in depressed ...
BioStem Technologies Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is transforming into a regenerative medicine platform with a focus on surgical and hospital markets, driven by strategic acquisitions and a robust clinical and IP foundation. Expansion into new markets and internalizing manufacturing are expected to improve margins and support sustained growth.
BioStem Technologies Slides: Corporate presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
BioStem Technologies Slides: Company presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
BioStem Technologies Earnings Call Transcript: Q4 2025
Q4 2025 revenue was $10.1M with 97% gross margin, but physician office sales declined due to CMS changes. The hospital segment is now the main growth driver, supported by the BioTissue acquisition and expanded product portfolio. Cash runway extends into late Q3 2026.
BioStem Technologies Earnings release: Q4 2025
BioStem Technologies released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
BioStem Technologies Slides: Company presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioStem Technologies Transcript: TD Cowen 46th Annual Health Care Conference
The company is evolving into a diversified regenerative medicine platform, expanding its addressable market through acquisitions and new technologies. Strong clinical evidence, a broadened reimbursement base, and operational investments position it for growth and a potential Nasdaq up-listing.
BioStem Technologies Slides: Company presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
BioStem Technologies Transcript: M&A announcement
The acquisition of BioTissue's surgical and wound care business doubles the addressable market, expands the product portfolio, and strengthens commercial reach, with $29 million in 2025 sales and 65% gross margins. Integration plans focus on seamless transition, tech transfer, and leveraging synergies for growth and profitability in 2026.
BioStem Technologies Press release: M&A announcement
BioStem Technologies issued a press release on January 22, 2026, disclosing material business information to investors.
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Earnings Call Transcript: Q3 2025
Delivered seventh straight quarter of positive adjusted EBITDA and industry-leading gross margins, despite lower revenue due to pricing pressures. Restated financials had no impact on EBITDA or net income. Positioned for growth with new clinical data, expanded market access, and upcoming CMS reimbursement reform.
BioStem Technologies Earnings release: Q3 2025
BioStem Technologies released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Technologies Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A medtech firm specializing in placental-based wound care is rapidly expanding through clinical validation, strategic partnerships, and efficient manufacturing. Regulatory changes and new clinical data are expected to shape future growth, with strong financial performance and ongoing M&A opportunities supporting long-term expansion.
BioStem Technologies Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A proprietary wound care technology platform is driving rapid revenue growth, with strong clinical trial progress and a robust patent portfolio. Anticipated reimbursement changes in 2026 are expected to support further expansion, while new leadership and strategic partnerships position the company for continued success.
BioStem Technologies Earnings Call Transcript: Q2 2025
Q2 2025 saw a 34% revenue decline year-over-year due to reimbursement uncertainty and competition, but gross margins improved to 98.6% and cash rose to $30.8 million. Strategic shifts and clinical progress aim to restore growth amid ongoing regulatory and market headwinds.
BioStem Technologies Quarterly report: Q2 2025
BioStem Technologies has published its Q2 2025 quarterly earnings report on August 14, 2025.